Key Insights

Highlights

Success Rate

86% trial completion

Published Results

24 trials with published results (15%)

Research Maturity

87 completed trials (53% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

8.5%

14 terminated out of 164 trials

Success Rate

86.1%

-0.4% vs benchmark

Late-Stage Pipeline

9%

14 trials in Phase 3/4

Results Transparency

28%

24 of 87 completed with results

Key Signals

24 with results86% success14 terminated

Data Visualizations

Phase Distribution

112Total
Not Applicable (54)
Early P 1 (4)
P 1 (15)
P 2 (25)
P 3 (10)
P 4 (4)

Trial Status

Completed87
Recruiting24
Unknown17
Terminated14
Withdrawn10
Not Yet Recruiting5

Trial Success Rate

86.1%

Benchmark: 86.6%

Based on 87 completed trials

Clinical Trials (164)

Showing 20 of 20 trials
NCT05925803Phase 3Active Not Recruiting

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT04797286Phase 2RecruitingPrimary

Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

NCT06587828Completed

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

NCT06373263Not ApplicableCompletedPrimary

Evaluating Tools to Communicate Scleroderma Research Results to Patients - Trial #1

NCT07641634Phase 1Recruiting

A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.

NCT06195072Phase 2Recruiting

Platform Clinical Study for Conquering Scleroderma

NCT06328777Phase 2Recruiting

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

NCT06646913Not ApplicableCompletedPrimary

TENS in Scleroderma

NCT06801119Phase 1Recruiting

Efficacy and Safety of HN2301 in Autoimmune Diseases(AIDs)

NCT06991114Phase 2Recruiting

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT06843239Phase 2Active Not Recruiting

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

NCT05098704Phase 2RecruitingPrimary

Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk

NCT07661836Not ApplicableActive Not RecruitingPrimary

Personalized Online Occupational Therapy Intervention for Adults With Scleroderma

NCT03800017Not ApplicableRecruiting

Skeletal Muscle Function in Interstitial Lung Disease

NCT03222492Phase 1Completed

Brentuximab Vedotin for Systemic Sclerosis

NCT05204355CompletedPrimary

MRI for Screening and Monitoring Scleroderma ILD

NCT06847750Enrolling By InvitationPrimary

Elastography Ultrasound in Localized Scleroderma (Morphea) Study

NCT06880627Not ApplicableActive Not RecruitingPrimary

Brain Boost Program to Improve Cognitive Function in People With Systemic Sclerosis

NCT05995626Early Phase 1Completed

Hyaluronidase Via LADD Scleroderma-induced Microstomia

NCT02450396Withdrawn

Pregnancy and Medically Assisted Conception in Rare Diseases

Scroll to load more

Research Network

Activity Timeline